Novel MTBR‐specific immunoassays MTBR‐1 and MTBR‐pTau262 for assessment of tau pathology in Alzheimer's disease

The MTBR1 assay represents the first high-performing immunoassay capable of detecting MTBR tau fragments in CSF, showing significant elevation in relation to both cognitive impairment severity and tau accumulation. In addition, MTBR-pTau262 emerges as a promising novel biomarker that reflects MTBR tau species in both CSF and plasma. These markers may serve as a valuable complement to existing plasma biomarkers, potentially improving accessibility and specificity in AD diagnostics and disease monitoring.